Focus on improving the development of new drugs! Qingpu Bio successfully obtained nearly 50 million yuan pre-A round financing.

Recently, Nanjing Qingpu Biotech Co., Ltd. ("Qingpu Bio"), which focuses on the research and development of improved new drugs in the field of pain, announced the completion of nearly 50 million yuan of pre-A round financing.
this round of financing led by Junlian Capital, Angel shareholders Windi Capital continues to participate in the investment.
Qingpu Bio focuses on the development of non-opioid analgesics, this round of financing will be mainly used to promote inD declaration and early clinical research of existing projects, further expand the size of the team, enrich the research and development pipeline, accelerate product development.
Pain field has clear unsoolfed clinical needs, the existing analgesic drugs are mainly opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), but opioids due to serious addiction has triggered a global crisis, NSAIDs are weak analgesic efficacy, mainly used for mild moderate pain.
there is a clinical need for non-opioid, long-acting, powerful analgesic products.
qingpu biological clinical needs-oriented, for different clinical applications, developed a wealth of analgesic drug product pipeline.
has a deep understanding of the clinical and market, can take full advantage of the advantages in preparation technology and clinical development, and quickly promote the approval of product pipelines to market.
Qingsong, founder of Qingpu Bio, said: "Thanks to investors for their recognition of the company's strategy, team and technology.
mainstream opioids currently used for analgesics are addictive, and the United States is experiencing a severe "opioid crisis" that requires better non-opioid analgesics clinically.
the establishment of Qingpu Bio, relying on independent research and development and multi-party cooperation, the establishment of a highly promising product pipeline, is expected to provide patients with safer and more effective analgesic drugs.
"About Clean Biology was established in 2017 as a clinically demand-oriented company focusing on improved new drugs in the pain field.
company has built its own intellectual property pipeline around the pain sector, and the fastest-growing project is nearing the completion of a clinical trial application (IND) declaration for new drugs in china and the United States.
team members mainly from well-known pharmaceutical companies at home and abroad, master's degree or above accounted for more than 80% of employees, more than 10 years of experience in the industry reached 50%.
Qingsong Wang, founder of the Company, has extensive business development experience in the pharmaceutical field and experience in research and development of new drugs, and has participated in the development of several listed innovative drugs/generic drugs.
Hu Ning, co-founder of the Company, has over 20 years of experience in the development and production of special agents such as liposomes, albumin nanoparticles and nanocrystals.
about Junlian Capital is an independent professional venture capital company owned by Lenovo Holdings, founded in April 2001.
core business is focused on start-up venture capital and expansion growth investments, focusing on TMT and investments in innovative consumer, professional services and smart manufacturing, healthcare, culture and sports.
the total size of U.S. dollar and RMB funds exceeds RMB50 billion, focusing on Innovation and Growth Opportunities in China.
2020, Junlian Capital has injected nearly 450 enterprises, of which more than 70 have successfully listed/listed at home or overseas, and more than 60 companies have exited through mergers and acquisitions.
the representative projects invested in the field of medical and health care are Pharmaceutical Mingkangde, Jin domain medicine, Kanglong cheng, Xinda Biology, Minder Biology and so on.
About Windi Capital, founded in 2015, focuses on investments in "early" and "long-term" companies in the healthcare sector, focusing on addressing unsolved clinical needs through technological innovation.
investment areas mainly include biomedicine, medical equipment, medical services, three major sectors.
to actively create value-creating investment as the core, based on a wealth of industrial resources, management experience and capital solutions, to help investment enterprises at all stages of development.
source: Medical Rubik's Cube!-- content display ends -- !-- to determine whether the login ends.